ArticleScience advances2022
Biodegradable silicon nanoneedles for ocular drug delivery.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Advancements and challenges in ophthalmic microneedles to treat eye diseases.Drug delivery · 2026Review
- Dual-Dynamically Crosslinked Nanogels Enable Prolonged Ocular Retention for Multimodal Dry Eye Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.Materials today. Bio · 2025Review
- A Focal Ophthalmic Lesion in a New Zealand White Rabbit (Oryctolagus cuniculus).Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Drug-free hyaluronic acid-microneedle with unexpected inhibition activity on benzalkonium chloride-induced corneal inflammation and stromal scarring.Materials today. Bio · 2025Article
- Advances in microneedle-based drug delivery system for metabolic diseases: structural considerations, design strategies, and future perspectives.Journal of nanobiotechnology · 2025Review
- Microfluidic contact lens: fabrication approaches and applications.Microsystems & nanoengineering · 2025Review
- An annular corneal microneedle patch for minimally invasive ophthalmic drug delivery.Science advances · 2025Article
- Long-Term Diabetic Retinopathy Treatment Using Silicon Nanoneedles.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Fish Fin-Derived Non-Invasive Flexible Bioinspired Contact Lens for Continuous Ophthalmic Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Microneedles for controlled and sustained intraocular drug delivery.NPG Asia materials · 2025Review
- Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.Pharmaceutics · 2024Review
- Advances in Polysaccharide-Based Microneedle Systems for the Treatment of Ocular Diseases.Nano-micro letters · 2024Review
- Integrating Porous Silicon Nanoneedles within Medical Devices for Nucleic Acid Nanoinjection.ACS nano · 2024Article
- Frequency-encoded eye tracking smart contact lens for human-machine interaction.Nature communications · 2024Article
- Bioinspired 3D flexible devices and functional systems.National science review · 2024Review
- Bioinspired Wet Adhesive Proanthocyanidins Microneedles for Ocular Wound Healing.Research (Washington, D.C.) · 2024Article
- GEOMETRIC DETERMINANTS OF CELL VIABILITY FOR 3D-PRINTED HOLLOW MICRONEEDLE ARRAY-MEDIATED DELIVERY.Proceedings. IEEE International Conference on Micro Electro Mechanical Systems · 2024Article
- TOWARD CONTROLLED-RELEASE DRUG DELIVERY MICROCARRIERS ENABLED BY DIRECT LASER WRITING 3D PRINTING.Proceedings. IEEE International Conference on Micro Electro Mechanical Systems · 2024Article
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ocular drug delivery remains a grand challenge due to the complex structure of the eye. Here, we introduce a unique platform of ocular drug delivery through the integration of silicon nanoneedles with a tear-soluble contact lens. The silicon nanoneedles can penetrate into the cornea in a minimally invasive manner and then undergo gradual degradation over the course of months, enabling painless and long-term sustained delivery of ocular drugs. The tear-soluble contact lens can fit a variety of corneal sizes and then quickly dissolve in tear fluid within a minute, enabling an initial burst release of anti-inflammatory drugs. We demonstrated the utility of this platform in effectively treating a chronic ocular disease, such as corneal neovascularization, in a rabbit model without showing a notable side effect over current standard therapies. This platform could also be useful in treating other chronic ocular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.